Gritstone Bio Revenue 2017-2022 | GRTS

Gritstone Bio revenue from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Gritstone Bio Annual Revenue
(Millions of US $)
2021 $48
2020 $4
2019 $4
2018 $1
2017 $
2016 $
Gritstone Bio Quarterly Revenue
(Millions of US $)
2022-03-31 $7
2021-12-31 $3
2021-09-30 $3
2021-06-30 $3
2021-03-31 $40
2020-12-31 $1
2020-09-30 $1
2020-06-30 $0
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $0
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.130B $0.048B
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00